Table 2.

Incidence rates for deep vein thrombosis and pulmonary embolism in tofacitinib clinical development studies

Adverse event	Placebo-controlled cohort			Dose-comparison cohort
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Adalimumab 40 mg SC q2w	MTX 20 mg qw
DVT	0/1849 0 (0–0.9)	0/2024 0 (0–0.8)	1/1079 0.4 (0–2.4)	1/1849 0.1 (0–0.3)	1/2024 0.1 (0–0.3)	0/257 0 (0–0.9)	2/220.7 (0.1–2.5)
PE	0/1849 0 (0–0.9)	0/2024 0 (0–0.8)	1/1079 0.4 (0–2.4)	2/1849 0.1 (0–0.4)	3/2024 0.2 (0–0.4)	0/257 0 (0–1.9)	0/223 0 (0–1.3)

The data include 5368 patients with rheumatoid arthritis and 4440 person-years. Data are presented as n/N and incidence rate (95% confidence interval)

BID twice daily, DVT deep vein thrombosis, IR incidence rates, MTX methotrexate, PE pulmonary embolism, q2w every 2 weeks, qw every week, SC subcutaneous